Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
The Rare Tumors Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center provides care for uncommon cancerous conditions. Among the cancers we treat are germ cell tumors of the brain, melanoma, and nasopharyngeal, adrenocortical and thyroid carcinomas.
Dana-Farber/Boston Children’s is an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital. We offer, in one specialized program, the full spectrum of services that are needed for diagnosis, treatment and ongoing care of even the rarest and hard-to-treat conditions.
The Rare Tumors Program features treatment teams led by pediatric oncologists with special expertise in treating many rare forms of cancer. They are supported by radiation oncologists, surgeons and pathologists, as well as specialists in neurology, endocrinology, dermatology, ophthalmology and other medical specialties.
Children in our program benefit from the work of our laboratory and clinical researchers, who focus on understanding the scientific causes of rare cancers, which results in new treatment options. Children with progressive or recurrent rare cancers may be eligible for experimental therapies and clinical trials.
Learn more about our Rare Tumors Program on the Dana-Farber/Boston Children’s website.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”